CURATODERM

This brand name is authorized in Austria, Poland, UK.

Active ingredients

The drug CURATODERM contains one active pharmaceutical ingredient (API):

1	Tacalcitol UNII B3Q63NVN9R - TACALCITOL MONOHYDRATE
	Tacalcitol is a vitamin D3 derivative, which inhibits keratinocyte hyper-proliferation and induces differentiation of these cells. The normalisation of these mechanisms is the basis for the efficacy in the treatment of psoriasis.
	Read more about Tacalcitol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CURATODERM Ointment	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D05AX04	Tacalcitol	D Dermatologicals → D05 Antipsoriatics → D05A Antipsoriatics for topical use → D05AX Other antipsoriatics for topical use
Discover more medicines within D05AX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
GB	Medicines & Healthcare Products Regulatory Agency	127734, 24541, 24544
PL	Rejestru Produktów Leczniczych	100077318